Jaffee EM - Search Results

1

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Hassan R, et al. Among authors: jaffee em. J Clin Oncol. 2016 Dec;34(34):4171-4179. doi: 10.1200/JCO.2016.68.3672. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27863199 Free PMC article. Review.

2

Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines.

Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM. Golumbek PT, et al. Among authors: jaffee em. J Immunother (1991). 1992 Nov;12(4):224-30. doi: 10.1097/00002371-199211000-00002. J Immunother (1991). 1992. PMID: 1335754

3

Gene therapy: its potential applications in the treatment of renal-cell carcinoma.

Jaffee EM, Pardoll DM. Jaffee EM, et al. Semin Oncol. 1995 Feb;22(1):81-91. Semin Oncol. 1995. PMID: 7855623 Review. No abstract available.

4

Enhanced immune priming with spatial distribution of paracrine cytokine vaccines.

Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Jaffee EM, et al. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):176-83. doi: 10.1097/00002371-199605000-00002. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8811492

5

Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines.

Jaffee EM, Pardoll DM. Jaffee EM, et al. Methods. 1997 Jun;12(2):143-53. doi: 10.1006/meth.1997.0463. Methods. 1997. PMID: 9184378 Review.

6

Cancer vaccines.

Greten TF, Jaffee EM. Greten TF, et al. Among authors: jaffee em. J Clin Oncol. 1999 Mar;17(3):1047-60. doi: 10.1200/JCO.1999.17.3.1047. J Clin Oncol. 1999. PMID: 10071300 Review.

7

Immunotherapy of cancer.

Jaffee EM. Jaffee EM. Ann N Y Acad Sci. 1999;886:67-72. doi: 10.1111/j.1749-6632.1999.tb09401.x. Ann N Y Acad Sci. 1999. PMID: 10667204 Review.

8

Potential role of tumor vaccines in GI malignancies.

Laheru DA, Jaffee EM. Laheru DA, et al. Among authors: jaffee em. Oncology (Williston Park). 2000 Feb;14(2):245-56; discussion 259-60, 265. Oncology (Williston Park). 2000. PMID: 10736811 Review.

9

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.

Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ. Jaffee EM, et al. J Clin Oncol. 2001 Jan 1;19(1):145-56. doi: 10.1200/JCO.2001.19.1.145. J Clin Oncol. 2001. PMID: 11134207 Clinical Trial.

10

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. Reilly RT, et al. Among authors: jaffee em. Cancer Res. 2001 Feb 1;61(3):880-3. Cancer Res. 2001. PMID: 11221874

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results